Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

Summary

This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants, children, and adolescents will receive a single 10 mg/kg dose of telavancin infused intravenously (IV) over 60 minutes

Timeline

Start

2014-12

Primary completion

2021-03

Completion

2021-03

Publications

• Bradley JS, Goldman JL, James LP, Kaelin B, Gibson BHY, Arrieta A. Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2-17 years of age. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0098723. doi: 10.1128/aac.00987-23. Epub 2023 Oct 10.

Drugs

Indications